Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up

Circulation. 2001 Oct 23;104(17):2007-11. doi: 10.1161/hc4201.098056.

Abstract

Background: We have previously reported a virtual absence of neointimal hyperplasia 4 months after implantation of sirolimus-eluting stents. The aim of the present investigation was to determine whether these results are sustained over a period of 1 year.

Methods and results: Forty-five patients with de novo coronary disease were successfully treated with the implantation of a single sirolimus-eluting Bx VELOCITY stent in São Paulo, Brazil (n=30, 15 fast release [group I, GI] and 15 slow release [GII]) and Rotterdam, The Netherlands (15 slow release, GIII). Angiographic and volumetric intravascular ultrasound (IVUS) follow-up was obtained at 4 and 12 months (GI and GII) and 6 months (GIII). In-stent minimal lumen diameter and percent diameter stenosis remained essentially unchanged in all groups (at 12 months, GI and GII; at 6 months, GIII). Follow-up in-lesion minimal lumen diameter was 2.28 mm (GIII), 2.32 mm (GI), and 2.48 mm (GII). No patient approached the >/=50% diameter stenosis at 1 year by angiography or IVUS assessment, and no edge restenosis was observed. Neointimal hyperplasia, as detected by IVUS, was virtually absent at 6 months (2+/-5% obstruction volume, GIII) and at 12 months (GI=2+/-5% and GII=2+/-3%).

Conclusions: This study demonstrates a sustained suppression of neointimal proliferation by sirolimus-eluting Bx VELOCITY stents 1 year after implantation.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Blood Vessel Prosthesis Implantation / adverse effects
  • Blood Vessel Prosthesis Implantation / instrumentation*
  • Blood Vessel Prosthesis Implantation / methods
  • Brazil
  • Cohort Studies
  • Coronary Angiography
  • Coronary Disease / diagnosis
  • Coronary Disease / drug therapy
  • Coronary Disease / surgery*
  • Delayed-Action Preparations / administration & dosage
  • Drug Implants / administration & dosage
  • Endosonography
  • Female
  • Follow-Up Studies
  • Graft Occlusion, Vascular / etiology
  • Graft Occlusion, Vascular / prevention & control*
  • Humans
  • Male
  • Middle Aged
  • Netherlands
  • Sirolimus / administration & dosage*
  • Sirolimus / adverse effects
  • Stents* / adverse effects
  • Survival Rate
  • Treatment Outcome
  • Tunica Intima / drug effects
  • Vascular Patency / drug effects

Substances

  • Delayed-Action Preparations
  • Drug Implants
  • Sirolimus